Economic evaluation of adjuvant trastuzumab emtansine in patients with her2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab–based treatment in Canada

T. Younis; A. Lee; M. E. Coombes; N. Bouganim; D. Becker; C. Revil; G. S. Jhuti

doi:10.3747/co.27.6517

Economic evaluation of adjuvant trastuzumab emtansine in patients with her2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab–based treatment in Canada

T. Younis, A. Lee, M. E. Coombes, N. Bouganim, D. Becker, C. Revil, G. S. Jhuti

Engineering

科研成果: 期刊稿件 › 文章 › 同行评审

7 引用（Scopus）

源语言	英语
页（从-至）	578-589
页数	12
期刊	Current Oncology
卷	27
期	6
DOI	https://doi.org/10.3747/co.27.6517
出版状态	已出版 - 12月 2020

!!!ASJC Scopus Subject Areas

肿瘤学

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.3747/co.27.6517

其它文件与链接

引用此

Younis, T., Lee, A., Coombes, M. E., Bouganim, N., Becker, D., Revil, C., & Jhuti, G. S. (2020). Economic evaluation of adjuvant trastuzumab emtansine in patients with her2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab–based treatment in Canada. Current Oncology, 27(6), 578-589. https://doi.org/10.3747/co.27.6517

Younis, T, Lee, A, Coombes, ME, Bouganim, N, Becker, D, Revil, C & Jhuti, GS 2020, 'Economic evaluation of adjuvant trastuzumab emtansine in patients with her2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab–based treatment in Canada', Current Oncology, 卷 27, 号码 6, 页码 578-589. https://doi.org/10.3747/co.27.6517

@article{720d4e72b997431f842a64610c8118fc,

title = "Economic evaluation of adjuvant trastuzumab emtansine in patients with her2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab–based treatment in Canada",

keywords = "Adjuvant her2-positive therapy, Cost–utility analyses, Early breast cancer, Economic evaluations, Trastuzumab emtansine",

author = "T. Younis and A. Lee and Coombes, {M. E.} and N. Bouganim and D. Becker and C. Revil and Jhuti, {G. S.}",

note = "Publisher Copyright: {\textcopyright} 2020 Multimed Inc.",

year = "2020",

month = dec,

doi = "10.3747/co.27.6517",

language = "English",

volume = "27",

pages = "578--589",

journal = "Current Oncology",

issn = "1198-0052",

publisher = "Multimed Inc.",

number = "6",

}

TY - JOUR

T1 - Economic evaluation of adjuvant trastuzumab emtansine in patients with her2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab–based treatment in Canada

AU - Younis, T.

AU - Lee, A.

AU - Coombes, M. E.

AU - Bouganim, N.

AU - Becker, D.

AU - Revil, C.

AU - Jhuti, G. S.

PY - 2020/12

Y1 - 2020/12

KW - Adjuvant her2-positive therapy

KW - Cost–utility analyses

KW - Early breast cancer

KW - Economic evaluations

KW - Trastuzumab emtansine

UR - http://www.scopus.com/inward/record.url?scp=85098723486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85098723486&partnerID=8YFLogxK

U2 - 10.3747/co.27.6517

DO - 10.3747/co.27.6517

M3 - Article

C2 - 33380873

AN - SCOPUS:85098723486

SN - 1198-0052

VL - 27

SP - 578

EP - 589

JO - Current Oncology

JF - Current Oncology

IS - 6

ER -

Economic evaluation of adjuvant trastuzumab emtansine in patients with her2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab–based treatment in Canada

!!!ASJC Scopus Subject Areas

联合国可持续发展目标

访问文件

其它文件与链接

指纹

引用此